Distribution of serum neuron-specific enolase and the establishment of a population reference interval in healthy adults

Qian Liu1 | Jilong Fan2 | Aiguo Xu3 | Li Yao1 | Yan Li1 | Wenjun Wang1 | Wei Liang1 | Fumeng Yang1

1Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, China
2Department of Hepatobiliary Surgery, The Second People's Hospital of Lianyungang, Lianyungang, China
3Department of Oncology, The Second People's Hospital of Lianyungang, Lianyungang, China

Correspondence
Fumeng Yang, Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, China.
Email: yfm31095018@163.com

Background: Neuron-specific enolase (NSE) is an important tumor marker in the serum of patients with lung cancer. Elevated serum NSE levels are also associated with many other diseases. However, there is no unified population reference interval for serum NSE. This study aimed to investigate the distribution of serum NSE in healthy Chinese adults aged 20-79 years and to establish its reference interval in Chinese population.

Methods: A total of 10,575 healthy subjects were in line with the requirements of this study. The concentration of serum NSE was detected by a fully automated Cobas e602 analyzer with matching reagents. The population reference interval for serum NSE was established using the unilateral 95th percentile ($P_{95}$) according to standard guidelines.

Results: The distributions of serum NSE were not significantly different between males and females ($P > 0.05$) and also did not differ by age ($P > 0.05$). Therefore, the population reference interval for serum NSE was established as upper limit 25.4 ng/mL (90% confidence interval: 24.5-26.2 ng/mL).

Conclusions: We established the first population reference interval for serum NSE in a large healthy Chinese adult cohort, which was higher than that recommended by Roche Diagnostics GmbH. This new reference interval is more practical and applicable in Chinese adults.

Keywords: neuron-specific enolase, population reference interval, serum

Abbreviations: AFP, alpha-fetoprotein; CA199, carbohydrate antigen 199; CEA, carcinoembryonic antigen; CI, confidence interval; FBG, fasting blood glucose; IQR, interquartile range; NSE, neuron-specific enolase; TC, total cholesterol; TG, triglycerides.

Liu and Fan are equal contributors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.
1 | INTRODUCTION

Lung cancer is the most commonly diagnosed cancer worldwide (11.6% of all cancer cases) and the leading cause of cancer death (18.4% of all cancer deaths). Lung cancer can be divided into two main types: non–small-cell lung cancer and small-cell lung cancer. About 80%–85% of lung cancers are non–small-cell lung cancer.

Neuron-specific enolase (NSE) is an important tumor marker in the serum of patients with lung cancer. Elevated serum NSE levels are also associated with neuroblastoma, neuroendocrine neoplasms, renal cell carcinoma, multiple myeloma, brain trauma, Guillain–Barre syndrome, and other diseases. Therefore, measurement of serum NSE can be used as an auxiliary marker for the diagnosis of several diseases. Currently, however, there is no unified population reference interval for serum NSE. Independent clinical laboratories often refer to the reagent manufacturer's instructions for the population reference interval for serum NSE. This interval has not been validated, however, and therefore, the utility of serum NSE is limited in clinical applications. Moreover, the tested level of serum NSE will also be affected by detection system, genotype, geographical location, lifestyle, and many other factors. Thus, the population reference interval of serum NSE could be variable in different population. However, most Chinese laboratories use the NSE population reference intervals either provided by abroad (Europe and the United States) laboratories or the reagent manual. These population reference intervals may not be suitable for Chinese population in clinical application. In order to establish a more specific and reliable population reference interval of serum NSE for Chinese population, we measured serum NSE in a large number of healthy adult subjects aged 20–79 years and established the population reference interval of serum NSE according to Clinical and Laboratory Standards Institute (CLSI) CA28–A3.

2 | MATERIAL AND METHODS

2.1 | Study subjects

A total of 11 000 subjects who completed a physical examination at the Physical Examination Center of the Second People's Hospital of Lianyungang from January 2017 to June 2018 were randomly selected as participants in this study. According to the inclusion and exclusion criteria, a total of 10 575 healthy individuals (5056 males and 5519 females; 20–79 years old) were in line with the requirements of the study. Participants were divided into 12 groups by sex (male and female) and age (20–29 years old; 30–39 years old; 40–49 years old; 50–59 years old; 60–69 years old; and 70–79 years old) as recommended by CLSI C28–A3 to determine whether the distribution of serum NSE levels differs by age and/or sex. The detailed screening procedures of the study participants are shown in Figure 1.

Participants in this study met the following inclusion criteria: (a) 20–79 years old; (b) blood pressure ≤139/89 mm Hg; (c) serum indices of samples were all negative (means no hemolysis, no icterus, and no lipemia); (d) routine biochemical indicators, such as serum urea, creatinine, total cholesterol, triglycerides, and fasting blood glucose, within the normal reference intervals; (e) negative for the presence of indicators of infectious diseases, such as hepatitis B, hepatitis C, and syphilis caused by Treponema pallidum; and (f) indicators for various tumors markers, such as CYFRA21-1, CA199, CEA, and AFP, within normal reference intervals (Table 1). Participants were excluded if they had (a) acute inflammation or infection; (b) acute or chronic liver, kidney, lung, brain, heart, or other systemic disease; (c) a history of surgery within the past 6 months; (d) a history of drug treatment in the past month; (e) recent diet; or (f) recent irregular work schedules, insufficient sleep, or excessive alcohol consumption. This study was approved
by the Medical Ethics Committee of the Second People’s Hospital of Lianyungang. Written informed consent was obtained from all participants.

2.2 | Specimen collection

Five milliliters of fasting venous blood was collected in the morning. The samples were centrifuged within 2 hours, and packed serum was stored at ~80°C until testing. Ten milliliters of fresh morning urine also was collected. Routine urine measurements were completed within 2 hours of collection.

2.3 | Instruments and reagents

To minimize analytical errors, the same lots of reagents, standards, and quality control materials (means to check system with traditional QC runs which helps detect both bias shifts and imprecision) were used throughout the analyses. Serum NSE levels were analyzed via electrochemiluminescence immunoassay (ECLIA) using a standard assay kit for in vitro diagnostics (NSE kit lot: 28293601; NSE calibrator lot: 27153901; Roche Diagnostics GmbH, Mannheim, Germany). Reactions and quantitation were performed using a fully automated Cobas e602 analyzer (Roche Diagnostics GmbH). Tumor marker substance controls (lot 1: 256628; lot2: 256629; Roche Diagnostics GmbH) were used to ensure the precision of the test results. Urinalysis was conducted using an HC900 automatic urine analyzer (Changchun Dirui Co., Ltd, Changchun, China). All instruments and equipment were maintained and calibrated according to the manufacturer’s instructions, and the indoor quality control and inter-room quality evaluation met all requirements prior to specimen evaluation.

2.4 | Statistical analyses

2.4.1 | Outlier test

According to the Dixon method recommended in the CLSI C28-A3 guidelines, the detection result is sorted by size to calculate the range, R. The distribution then is used to calculate the difference (D) between the maximum value and the minimum value and its adjacent value. If D/R ≥ 1/3, then the maximum or minimum value is treated as an outlier. This process is repeated on the remaining data until all outliers are eliminated.

2.4.2 | Identification of biological reference interval groups

We referred to the recommended methods in CLSI C28-A3 and WS/T 402-2012 (“Establishment of reference interval for clinical laboratory test items”), and applied the Z test to determine whether the data from two comparison groups can be combined. The formula for the Z test is:

$$Z = \frac{\bar{x}_1 - \bar{x}_2}{\sqrt{\frac{s_1^2}{n_1} + \frac{s_2^2}{n_2}}}$$

where $\bar{x}_1$ and $\bar{x}_2$ represent the mean values from the two groups, $s_1$ and $s_2$ represent the standard deviations from the two groups, and $n_1$ and $n_2$ represent the sample sizes of the two groups. If $Z > Z^*$, then the difference between the reference intervals is statistically significant ($P < 0.05$) and the reference intervals for the two groups should

### TABLE 1 Normal reference interval of routine indicators

| Parameters   | Reference interval | Units of measurement |
|--------------|--------------------|----------------------|
| Urea         | 3.1-8.0 (male, ages 20-59) | mmol/L               |
|              | 3.6-9.5 (male, ages 60-79) |                      |
|              | 2.6-7.5 (female, ages 20-59) |                     |
|              | 3.1-8.8 (female, ages 60-79) |                     |
| Creatinine   | 57-97 (male, ages 20-59) | μmol/L               |
|              | 57-111 (male, ages 60-79) |                      |
|              | 41-73 (female, ages 20-59) |                      |
|              | 41-81 (female, ages 60-79) |                      |
| TC           | <200 mg/dL         |                      |
| TG           | <150 mg/dL         |                      |
| FBG          | 70-110 mg/dL       |                      |
| Hepatitis B  | Negative           |                      |
| Hepatitis C  | Negative           |                      |
| Syphilis     | Negative           |                      |
| CYFRA21-1    | <3.3 ng/mL         |                      |
| CA199        | <27 U/mL           |                      |
| CEA          | <4.7 ng/mL         |                      |
| AFP          | <7.0 ng/mL         |                      |

AFP, alpha fetoprotein; CA199, carbohydrate antigen 199; CEA, carcinoembryonic antigen; FBG, fasting blood glucose; TC, total cholesterol; TG, triglycerides.

![Distribution histogram of serum neuron-specific enolase (NSE) levels](image)
In contrast, if \( Z < Z^* \), then the difference between the two reference intervals is not statistically significant (\( P > 0.05 \)), and the intervals can be merged into one interval.

### 2.4.3 Statistical analysis

The data were analyzed in IBM SPSS Statistics version 20 (Armonk, NY, USA). The Kolmogorov-Smirnov test was applied to test the normality of the data. Non-normal data were expressed using the median and interquartile range (IQR), and the Kruskal-Wallis H test was used to compare across multiple groups. Non-parametric (ranked) method was used to establish reference interval by CLSI C28-A3. A \( P \)-value <0.05 was considered statistically significant.

#### Table 2: Distribution of serum neuron-specific enolase (NSE) by sex

| Gender | n   | Median (IQR)   | Upper limit (90% CI) | \( Z \) test |
|--------|-----|----------------|----------------------|-------------|
| Male   | 5056| 15.3 (13.8-15.9) | 25.5 (24.7-26.5) | \( Z < Z^* \) \( P > 0.05 \) |
| Female | 5519| 14.7 (12.4-15.9) | 24.8 (23.9-25.8) |             |
| Total  | 10575| 15.3 (13.8-15.9) | 25.4 (24.5-26.2) |             |

CI, confidence interval; IQR, interquartile range.
The unit of NSE is ng/mL.

**TABLE 3** Distribution of serum neuron-specific enolase (NSE) by age

| Age group   | n   | Median (IQR)   | Upper limit (90% CI) | \( H \)-value | \( P \)-value |
|-------------|-----|----------------|----------------------|---------------|--------------|
| 20-29 (male)| 224 | 15.2 (13.7-15.8) | 24.1 (20.2-29.2) | 7.66          | 0.18         |
| 30-39 (male)| 743 | 15.3 (13.7-15.9) | 24.1 (21.3-26.0) |               |              |
| 40-49 (male)| 1235| 15.4 (14.2-15.9) | 26.8 (24.0-27.9) |               |              |
| 50-59 (male)| 1248| 15.3 (13.9-15.9) | 24.9 (23.9-26.4) |               |              |
| 60-69 (male)| 905 | 15.3 (13.7-15.9) | 25.1 (23.3-27.0) |               |              |
| 70-79 (male)| 701 | 15.3 (13.7-15.9) | 24.7 (23.4-25.8) |               |              |
| 20-29 (female)| 351 | 15.1 (13.1-16.3) | 24.6 (23.8-25.8) | 9.27          | 0.10         |
| 30-39 (female)| 809 | 14.5 (12.2-16.0) | 26.4 (24.8-27.7) |               |              |
| 40-49 (female)| 1350| 14.7 (12.4-16.2) | 24.6 (23.9-25.4) |               |              |
| 50-59 (female)| 1143| 14.8 (12.5-16.3) | 26.4 (24.6-27.7) |               |              |
| 60-69 (female)| 1021| 14.5 (12.2-15.9) | 20.8 (17.2-26.4) |               |              |
| 70-79 (female)| 845 | 14.9 (12.6-15.8) | 20.8 (17.3-26.4) |               |              |

IQR, interquartile range.
The \( H \)-value is the approximate \( \chi^2 \) value.
The unit of NSE is ng/mL.

### 3 RESULTS

A total of 10,575 individuals were ultimately retained for inclusion in this study, including 5056 males and 5519 females. Kolmogorov-Smirnov test showed a skewed distribution for serum NSE level (\( P < 0.05 \), Figure 2). The distribution of serum NSE levels was not significantly different between males and females, which indicated that the levels of NSE were not correlated with gender (\( Z = 4.89, Z^* = 19.91, P > 0.05 \); Table 2). Furthermore, no significant age-related differences in serum NSE levels were observed, which showed that the levels of NSE were not correlated with age (\( P > 0.05 \); Table 3).

In accordance with non-parametric method recommended by CLSI C28-A3 and WS/T 402-2012, the upper reference limit is important, which was set at the 95th percentile value. Accordingly, the population reference interval for serum NSE was established as upper limit 25.4 ng/mL by using the method of ECLIA in this study.

### 4 DISCUSSION

As an important tumor marker, serum NSE has been widely clinically used in the world.\(^{14,15} \) Just like other markers, a measurement result of serum NSE by itself without any appropriate reference interval or medical decision limit is of little value. The reference interval is essential for the interpretation of clinical laboratory results and patient
care.16 Thus, the development of an appropriate reference interval can provide an important basis for the diagnosis, progression, and prognosis of clinical diseases.17 However, the establishment of reference interval is constrained and influenced by many factors, such as ethnic characteristics and living environment.18,19 And regrettably, there have been only little reports about the establishment of serum NSE reference interval in healthy population up to date. Therefore, this is, to the best of our knowledge, the first study to establish the reference interval of serum NSE by using ECLIA in a large sample size of healthy Chinese population.

In this study, all subjects were rigorously screened, and 10,575 participants met the requirements to be included in the construction of the serum NSE reference interval. Rigorous statistical analyses were applied to show that the distribution of serum NSE levels was not significantly different between males and females (P > 0.05). In a similar study, Wen et al conducted a serum NSE reference interval study among healthy adults ranging in age from 17 to 62 years and reported no sex differences in serum NSE levels,20 which is consistent with our findings. In contrast, Li et al21 reported significant differences in serum NSE levels by sex and established separate reference intervals for males and females. Equivocal findings across studies may be due to sampling error, different regional characteristics, differences between individuals, or different detection methods.

The present study followed the recommendations set forth by the CLSI C28-A3 to examine interval ranges by age.12 No significant differences in serum NSE levels were observed in our participant cohort (P > 0.05). This finding is consistent with a previous study by Guo et al22, which reported no differences in serum NSE levels across 148 healthy adults aged 17-85 years. These previous findings are therefore consistent with the results of our study and support our determination of a common population reference interval for serum NSE levels for males and females between the ages of 20 and 79 years old.

This study established a serum NSE population reference interval of upper limit 25.4 ng/mL (90% confidence interval: 24.5–26.2), which is significantly higher than the reference interval stated by Roche Diagnostics GmbH. The upper limit of the reference interval provided by the Roche NSE kit is 17.0 ng/mL.23 This difference may be due to population disparities and inter-individual variation in the cohort used to construct the interval. Approximately 20% of healthy individuals exhibited elevated NSE levels based on the reference interval provided by the kit, even though all other indicators were normal. Our findings indicate, however, that the upper limit of the kit’s reference interval is too low. Under the new reference interval established in our study, these individuals would fall within the normal reference interval, significantly reducing false-positive results.

In summary, we established the reference interval for serum NSE using ECLIA in large-scale healthy Chinese population. Furthermore, the findings from this study suggest that every laboratory should establish a serum NSE population reference interval that accounts for the regional population, factors in the regional environment, and detection system characteristics.

ACKNOWLEDGMENTS

This study was supported in part by grants from Health Scientific Research Project in Lianyungang (201721, 201817), Young and Middle-aged Talents Growth Foundation of the Second People’s Hospital of Lianyungang (TQ201709), and Research projects of Bengbu Medical College (BYKY17184).

AUTHORS’ CONTRIBUTIONS

QL and FY conceived and designed the experiments. QL, JF, AX, and LY performed the experiments. YL, WW, and WL analyzed the data. QL, JF, and FY wrote the paper.

ORCID

Fumeng Yang https://orcid.org/0000-0002-2636-7340

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Peng Y, Wang Y, Li J, et al. Utility of NSE, Pro GRP and LDH in diagnosis and treatment in patients with small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2016;19(9):590-594.
3. Jiang ZF, Wang M, Xu JL. Thyminde kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci. 2018;194:1-6.
4. Xu L, Wang L, Yin X. The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer. Open Med. 2016;11(1):59-62.
5. Bai Y, Shen W, Zhu M, et al. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer. J Cell Biochem. 2019;120(1):105-114.
6. Isgrò MA, Bottoni P, Scatena R. Neuro-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:125-143.
7. Yang H, Mi R, Wang Q, et al. Expression of neuron-specific enolase in multiple myeloma and implications for clinical diagnosis and treatment. PLoS ONE. 2014;9(5):e94304.
8. Abbasoglu A, Sarialioglu F, Yazici N, et al. Serum neuron-specific enolase levels in preterm and term newborns and in infants 1–3 months of age. Pediatr Neonatol. 2015;56(2):114-119.
9. Georgantzí K, Sköldenberg EG, Stridsberg M, et al. Chromogranin A and neuron-specific enolase in neuroblastoma: correlation to stage and prognostic factors. Pediatr Hematol Oncol. 2018;35(2):156-165.
10. Wang W, Li TT, Zhao HJ, et al. Analysis of survey for implementation of professional standards of reference intervals in routine biochemistry laboratories. Chin J Clin Lab Sci. 2018;36(3):221-226.
11. Zhang GM, Bai SM, Zhang GM, et al. Reference intervals of carbohydrate antigen 19–9 in the apparently healthy adult population. J Clin Lab Anal. 2018;32(5):e22380.
12. CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
13. The Ministry of Health of the People’s Republic of China. WS/T 402-2012 clinical laboratory test project reference range. Beijing, China: Standard Press; 2013.
14. Oya Y, Yoshida T, Uemura T, et al. Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with
ALK rearrangement-positive non-small cell lung cancer: a case report. Oncol Lett. 2018;16(4):4219-4222.

15. Tang H, Bai Y, Shen W, et al. Clinical significance of combined detection of interleukin-6 and tumour markers in lung cancer. Autoimmunity. 2018;51(4):191-198.

16. Zhao B, Zhang M, Liu D, et al. Establishment of reference interval for the tumour marker serum CYFRA 21-1 in healthy Chinese Han ethnic adults. Scand J Clin Lab Invest. 2018;78:171-174.

17. Liu Q, Yang FM, Xu TD, et al. Establishment of biological reference interval for urinary podocalyxin in adults in Lianyungang. Chin J Pract Med. 2018;45(13):36-39.

18. Das M, Borah NC, Ghose M, et al. Reference ranges for serum uric acid among healthy Assamese people. Biochem Res Int. 2014;2014:1-7.

19. Dillane P, Krump L, Kennedy A, et al. Establishing blood gas ranges in healthy bovine neonates differentiated by age, sex, and breed type. J Dairy Sci. 2018;101(4):3205-3212.

20. Wen ZH, Chen WG, Chu JZ. Health-based reference measuring influential factors detecting and clinical applying of NSE. Acta Academiae Medicinae Hubei. 2000;21(2):144-146.

21. Li D, Lu Y, Liu XD. Establishment of the reference range of multi-tumor markers for healthy people in Shanghai. Lab Immun Clin Med. 2014;21(5):593-595.

22. Guo GH, Zhou HP, Tian YP, et al. Investigation of serum neuron-specific enolase levels in healthy adults in Beijing area. J Clin Lab Sci. 2002;20(5):278-278.

23. Matyar S, Goruroglu O, Ziyanoglu KE, et al. Biological variation and reference change value data for serum neuron-specific enolase in a Turkish population. J Clin Lab Anal. 2016;30(6):1081-1085.

How to cite this article: Liu Q, Fan J, Xu A, et al. Distribution of serum neuron-specific enolase and the establishment of a population reference interval in healthy adults. J Clin Lab Anal. 2019;33:e22863. https://doi.org/10.1002/jcla.22863